Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | LYN | P07948 | 4/20 | 1.00 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.81 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.81 |
| ▸ | SRC | P12931 | 3/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.75 |
| ▸ | TEK | Q02763 | 1/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.71 |
| ▸ | PRKDC | P78527 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 5/20 | 0.70 |
| ▸ | TEC | P42680 | 4/20 | 0.68 |
| ▸ | BMX | P51813 | 4/20 | 0.68 |
| ▸ | ITK | Q08881 | 3/20 | 0.68 |
| ▸ | BLK | P51451 | 3/20 | 0.68 |
| ▸ | TXK | P42681 | 2/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586962 | 1.00 | BTK (1.00) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL17713980 | 0.99 | BTK (0.98) | BTKLCKLYNNUDT14NUDT5 | |
| Pyrimidine SCHEMBL7047852 | 0.95 | BTK (0.90) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL15915382 | 0.91 | BTK (0.84) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL2631407 | 0.91 | BTK (0.84) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL5801169 | 0.90 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL5803102 | 0.90 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243244 | 0.90 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243281 | 0.90 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL29441896 | 0.90 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250295655-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | Alk-Abelló A/S (DK) | 2025-09-25 | — | — | US | claimed |
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY INC (US) | 2025-05-15 | — | — | US | claimed |
| EP-4531856-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK-Abelló A/S (DK) | 2025-04-09 | — | — | EP | claimed |
| EP-4472637-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | Kura Oncology, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| CN-118161618-A | Combination product comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL inhibitor and use thereof | 苏州亚盛药业有限公司 | 2024-06-11 | — | — | CN | claimed |
| US-20240026461-A1 | BCL10 MUTATIONS AS BIOMARKERS FOR TARGETED THERAPY IN B CELL LYMPHOMAS | MELNICK ARI (US) | 2024-01-25 | — | — | US | claimed |
| WO-2023240258-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023232958-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | Alk-Abelló A/S (DK) | 2023-12-07 | — | — | WO | claimed |
| WO-2023172640-A1 | TREATMENTS FOR SINGLE-MUTANT WALDENSTRÖM'S MACROGLOBULINEMIA | X4 PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | claimed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | disclosed |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025217164-A1 | TREATING INFLAMMATORY COMMON VARIABLE IMMUNODEFICIENCY WITH A BRUTON'S TYROSINE KINASE INHIBITOR | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | MEN1, ABCB1, ABCC1 | BTK 990/4885LCK 4446/4885LYN 3458/4885 |
| US-20250295655-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | BTK, SYK, ABL1 | BTK 1/4885LCK 5/4885LYN 4/4885 |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | CXCR6, BCL6, CXCR4 | BTK 33/4885LCK 366/4885LYN 428/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | BTK 1020/4885LCK 1011/4885LYN 1034/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | BTK 48/4885LCK 1736/4885LYN 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.